Evaluating the role of advanced imaging in gynecological cancers
Official title: Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)
Run by Region Västerbotten · NCT05855941 · Data updated 2026-11-12
This study is testing if advanced imaging techniques can help doctors better diagnose and treat women with cervical, endometrial, and ovarian cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | Region Västerbotten Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Umeå) |
| Status | Recruiting |
| Started | May 23, 2023 |
| Main results expected | May 2032 |
| Study ends | May 2032 |
| Registry record updated | December 16, 2024 |
| Trial ID | NCT05855941 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 with newly diagnosed, untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.
✕Probably not a fit
Patients with imaging findings suggestive of other primary malignancies or those who are MRI incompatible will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the added diagnostic and prognostic value of advanced medical imaging techniques, such as FDG-PET/CT and FDG-PET/MRI, in patients with cervical, endometrial, and epithelial ovarian cancers. Participants will undergo four additional imaging procedures beyond standard clinical examinations and will be followed for five years to evaluate survival predictions and improve radiotherapy planning. The study includes both retrospective validation of imaging against clinical staging and prospective identification of prognostic biomarkers. Additionally, it seeks to enhance non-invasive lymph node staging and develop a machine learning tool for ovarian lesion characterization.
Why it matters
Potential benefit: If successful, this study could lead to improved survival predictions and more effective treatment planning for patients with gynecological cancers.
How similar studies have gone: Other studies have shown promise in using advanced imaging techniques for cancer diagnosis and treatment planning, suggesting a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer. * Known clinical FIGO stage. * \>18 years old. * No other known current or previous malignancy within the last 10 years. Exclusion Criteria: * Imaging findings suggestive of other primary malignancy. * Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or "cancer abdominis". * MRI incompatible devices or patient unable to undergo MRI.
Where it's running
-
Centre for Gynecology and Obstetrics, Umea University Hospital
Umeå, Sweden Recruiting
Study contacts
- Principal investigator: Sara Strandberg, MD, PhD — Department of Radiation Sciences, Umea University/Radiology, Umea University Hospital
- Study coordinator: Erika Figaro
- Email: erika.figaro@regionvasterbotten.se
- Phone: +46907850499
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Shorter pelvic radiotherapy after surgery for cervical or endometrial cancer
A randomized study tests whether a shorter course of postoperative whole-pelvic radiotherapy can be as safe and effective as the standard longer schedule for women with cervical or endometrial cancer.
-
Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer
This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.
-
Testing a new drug ETX-19477 for advanced solid tumors
This study is testing a new drug called ETX-19477 to see if it can help people with advanced solid tumors that haven't responded to other treatments.
-
Treatment of advanced solid tumors with AVZO-021
This study is testing a new oral medication called AVZO-021 to see if it can safely help people with advanced solid tumors, especially certain types of breast cancer and other cancers with specific genetic changes.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.